Description
Title: Factors Affecting the Overall and Progression-Free Survival of Philadelphia-Positive Chronic Myeloid Leukemia in Nigerian Patients
Abstract: Objective. Tyrosine kinase inhibitors for patients with Ph+ and/or BCR-ABL1+ chronic myeloid leukemia have significantly altered the course of their disease (CML). The goal of this study was to evaluate the long-term effects of imatinib therapy on survival in adult CML patients from Nigeria. Methods. We evaluated every adult patient treated with imatinib (400–600mg) between July 2003 and December 2010. The gender split was 171/101, with a median age of 38 years (range, 20–75). Using Kaplan-Meier methods, overall survival (OS) and progression-free survival (PFS) were calculated. Results. At the time imatinib treatment began, 205 of the 272 patients were in the chronic phase, 54 were in the accelerated phase, and five were in the blastic phase. 222 people were still alive as of December 2010. OS was 94% and 63% at 1 and 5 years, respectively, while PFS was 89% and 54%. Similar results were found for the 205 patients in the chronic phase, where OS at 1 and 5 years was 97% and 68%, and PFS was 92% and 57%. Conclusion. The use of imatinib as first-line therapy for the treatment of CML has been further supported in our patients thanks to increased survival and decreased morbidity, which are comparable to results in other populations.
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Medicine
Sub Category: Hematology
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.